Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-09-03 21:34:14 ET · period of report 2026-09-01 · accession 0001636282-26-000111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-03 21:34 | 2026-09-01+ | SYRE | King-Jones Heidy | See Remarks | M - OptEx | $14.50 | +28.4K | 3,245 | New | +$411.8K |
| DMT | 2026-09-03 21:34 | 2026-09-01+ | SYRE | King-Jones Heidy | See Remarks | S - Sale+OE | $87.35 | -28.4K | 2,845 | -91% | -$2.48M |
| DMT | 2026-09-03 21:34 | 2026-09-01+ | SYRE | King-Jones Heidy | See Remarks | M - OptEx | $0.00 | -28.4K | 511.4K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | M | A | 27,999 | $14.50 | 30,844 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 2 | Common | Common Stock | 2026-09-01 | S | D | 4,845 | $86.40 | 25,999 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F3) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 3 | Common | Common Stock | 2026-09-01 | S | D | 16,548 | $87.20 | 9,451 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 4 | Common | Common Stock | 2026-09-01 | S | D | 6,206 | $88.17 | 3,245 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F5) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 5 | Common | Common Stock | 2026-09-01 | S | D | 400 | $89.38 | 2,845 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 6 | Common | Common Stock | 2026-09-02 | M | A | 400 | $14.50 | 3,245 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 7 | Common | Common Stock | 2026-09-02 | S | D | 400 | $90.00 | 2,845 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F2) Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-09-01 | M | D | 27,999 | $0.00 | 511,811 | D | $14.50 · — to 2033-09-01 | 27,999 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F6) This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-09-02 | M | D | 400 | $0.00 | 511,411 | D | $14.50 · — to 2033-09-01 | 400 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. (F6) This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |